ROXUS® RISES TO THE OCCASION WITH THE NEXT GENERATION OF RAPID-ACTING INTRANASAL PDE-5 TREATMENT

Revolutionary Nasal Spray Formulation Delivers Rapid Onset 4x Faster than Traditional Oral Tablets on the Market

SALT LAKE CITY, Oct. 5, 2026 /PRNewswire/ -- Today, men's health platform Mavrox, announced the launch of Roxus^®, an intranasal delivery for erectile dysfunction. By bypassing hepatic first-pass metabolism, Roxus^® acts faster at a lower dose with no pills to swallow, and no digestive delays. Men who are currently experiencing erectile dysfunction (ED) can finally stand at attention.

Formulated with vardenafil, a prescription medication used to treat ED in men, Roxus^® is administered directly through the nasal membrane, rather than passing through the digestive tract, which typically degrades 90% to 95% of an oral dose. A test by The Journal of Sexual Medicine found that when vardenafil is delivered as a nasal spray, it is able to reach the bloodstream in 10 minutes, compared to the traditional oral tablets that typically take 30-150 minutes to activate.

This innovative nasal spray is designed to reach clinical efficacy faster and at a lower required dose, offering patients a highly responsive, lower-exposure alternative to traditional ED medications.

"Erectile Dysfunction is something so many men silently struggle with, and let's be honest, nobody likes scheduling sex an hour in advance," said Morley Baker, CEO of Mavrox. "With Roxus^®, we're bringing a breakthrough solution and a first-of-its-kind innovation to men's health that relieves that pressure, and empowers men to restore true spontaneity back into their relationships."

Roxus^® is self-administered using a simple, metered nasal spray, with a recommended usage of one spray per nostril per application (not to exceed two applications, or 5mg, within 24 hours). Roxus^® is designed for men with a clinical ED diagnosis, who have experienced the letdown of intolerable side effects from every day oral options. By choosing Roxus^®,  potential benefits include:

• Rapid onset: Onset in as little as five minutes, under 10 minutes to noticeable effect, enabling greater spontaneity than oral tablets.
• Lower dose required: Comparable plasma concentrations with 5mg intranasal versus 10mg oral, reducing overall drug exposure.
• Consistent, well-tolerated effects: Less pharmacokinetic variability and a systemic adverse event profile comparable to oral PDE-5 inhibitors.
• Alternative delivery route: A personalized option for patients with dysphagia, difficulty swallowing, or inconsistent response to oral therapy.

Roxus^® is available following an eligibility review by a licensed clinician on Mavrox.com. Upon completion and approval, users can sign up for one, two and three-month subscription packages starting at $199 for one month (14 doses) up to $499 for three months (42 doses). Stay ready on the latest by heading to Mavrox.com and following @trymavrox on Instagram and TikTok.

About Mavrox
Mavrox is Shed's consumer-facing men's health platform. Through licensed providers, innovative treatment options, and a seamless telehealth experience, Mavrox helps men access effective healthcare with ease. Mavrox will be the exclusive U.S. telehealth platform offering ROXUS® during the medication's initial launch period.

Learn more at Mavrox.com.

About ROXUS^®
ROXUS^® is LTR Pharma's personalized medicine treatment for erectile dysfunction. Its rapid-acting intranasal delivery system is designed to provide onset in as little as five minutes¹, offering a highly effective alternative to traditional oral ED medications.

Disclaimer: ROXUS^® is a compounded prescription medication and has not been approved by the U.S. Food and Drug Administration. Prescription required. Treatment is available only after evaluation by a licensed healthcare provider to determine whether it is clinically appropriate. Individual results may vary.

FOR MORE INFORMATION:
[email protected]

SOURCE Mavrox